Eugia Pharma Specialities receives USFDA warning for Unit III

16 Aug 2024

Eugia Pharma Specialities receives USFDA warning for Unit III

Aurobindo Pharma announced that the USFDA has issued a warning letter for Unit-III of Eugia Pharma Specialities, a subsidiary of the company. There is no impact on the existing supplies to the US market.

The warning letter comes subsequent to receiving the Official Action Indicated (OAI) status from USFDA earlier in May 2024.

Top Blogs

blog-article-image-one

Share Market

Low Price Shares

0 mins read . Dec 18, 2024

blog-article-image-one

Share Market

Nifty 50 Top 10 Stocks

0 mins read . Dec 18, 2024

blog-article-image-one

Share Market

Best Stocks in 2025

0 mins read . Dec 18, 2024

Built for those who know the

game inside-out.

#ItsATraderThing

Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions